NCT04158817View on ClinicalTrials.gov

68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Prostate Cancer
Interventions
DRUG

68Ga-Labeled PSMA

All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.

DRUG

Non-labeled PSMA

Patient will be injected with microdose (\<100 ug) of THP-PSMA

Trial Locations (1)

Unknown

Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

NanoMab Technology (UK) Limited

INDUSTRY

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT04158817 - 68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage | Biotech Hunter | Biotech Hunter